acetylshikonin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bai, S; Fan, C; Hao, G; Jiang, H; Qiu, Y; Sun, L; Wu, M; Yang, Z; Yu, L; Zhai, J; Zhang, Y | 1 |
1 other study(ies) available for acetylshikonin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Article | Year |
---|---|
Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
Topics: Animals; Anthraquinones; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line; Cell Proliferation; Chlorocebus aethiops; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Signal Transduction; Vero Cells | 2020 |